papillary hyperplasia

Clinicopathological study of benign and malignant papillary hyperplasia of nodular goiter

结节性甲状腺肿伴良恶性乳头状增生的临床病理分析

Results : CK19 , S-100 and EMA are negative in all papillary hyperplasia .

结果：在乳头状增生中，CK19、S-100和EMA均不表达。

Retrospective study of 56 cases of papillary hyperplasia of thyroid gland

56例甲状腺乳头状增生性病变的回顾性研究

Role of thyroperoxidase in differential diagnosis between malignant and benign thyroid papillary hyperplasia

TPO在甲状腺乳头状癌与乳头状增生鉴别诊断中的作用

Conclusion High Molecular Weight keratin and TPO protein are useful markers in the different diagnosis between malignant and benign thyroid papillary hyperplasia .

结论高分子量角蛋白和TPO蛋白均可作为鉴别甲状腺乳头状癌与结甲伴乳头状增生等良性病变的重要参考标志物，联合测定效果更好。

LN expression in the cytoplasm of tumor cells of carcinoma and papillary hyperplasia in the follicular adenoma may indicate the malignant transformation .

LN免疫反应物出现于肿瘤细胞胞浆很可能是良性肿瘤转化为癌的标志。

Positive immunostaining of LN also was found in the cytoplasm of tumor cells of carcinoma and papillary hyperplasia appeared in the follicular adenoma .

LN在甲状腺癌细胞及出现于甲状腺滤泡性腺瘤组织中的乳头状腺瘤细胞胞浆中有表达。

Fifty-six cases of papillary hyperplasia of thyroid gland were reexamined by means of routine HE staining and light microscope in order to study the relationship between the morphology of some papillary hyperplasia and the prognosis of patients .

收集56例甲状腺乳头状增生性病变的临床病理资料，试图进一步探讨此类病变形态学各个方面与患者预后的关系。

The values of TPO in the different diagnosis between malignant and benign thyroid papillary hyperplasia were assessed below : sensitivity was 96 % , specificity was 100 % , accuracy was 98 % , + PV was 100 % , and-PV was 96.15 % .

TPO在甲状腺乳头状癌与良性乳头状增生鉴别诊断中的评价指标：敏感度为96%，特异度为100%，准确度为98%，阳性预测值为100%，阴性预测值为96.15%。

CK19 are valuable markers in the distinction of papillary carcinoma from papillary hyperplasia .

CK19在区分甲状腺乳头状癌和乳头状增生中是一个很好的标志物。

Differential diagnostic usefulness of CK19 , S-100 protein and EMA in papillary carcinoma and papillary hyperplasia

CK19，S-100和EMA在鉴别甲状腺乳头状癌与乳头状增生中的作用

Differential diagnosis of papillary thyroid carcinoma from papillary thyroid hyperplasia by immunohistochemistry

甲状腺乳头状癌与乳头状增生的免疫组化鉴别诊断

Expression of CK-19 in peripheral blood of patients with papillary thyroid carcinoma and papillary thyroid hyperplasia

CK-19在甲状腺乳头状癌及甲状腺乳头状增生患者外周血中的表达

Conclusion Galectin-3 , CK19 and Ki-67 were useful makers to distinguish the papillary thyroid carcinoma from papillary thyroid hyperplasia , especially combined application .

结论Galectin3，CK19及Ki-67是鉴别诊断甲状腺乳头状癌与乳头状增生的有用标志物，尤其联合使用更有价值。

Objective To study the expression of Galectin-3 , CK19 and Ki-67 in the papillary thyroid carcinoma and papillary thyroid hyperplasia and to find the differential diagnostic makers .

目的探讨Galectin3，CK19及Ki-67在甲状腺乳头状癌与乳头状增生中的表达，寻找有助于两者鉴别诊断的标志物。

Purpose : To evaluate the diagnostic utility of detection of Cytokeratin 19 ( CK19 ), b-100 protein and epithelial membrane antigen ( EMA ) in thyroid papillary carcinoma , follicular carcinoma and papillary hyperplasia .

目的：评估检测CK19、S-100蛋白和EMA在诊断甲状腺乳头状癌、滤泡性癌及乳头状增生中的作用。

There were significant differences in the feature of papillary and shape of nucleus between benign papillary hyperplasia and malignant papillary hyperplasia .

经常规HE染色，光镜检查，根据近期共认标准重新诊断，结果表明，良恶性乳头状增生病变乳头的结构和细胞核的形态存在明显差异。

Pathological examinations revealed 3 cases of well-differentiated papillary adenocarcinoma of the duodenum , 1 case of endocrine small-cell carcinoma of the head of pancreas , and 1 case of papillary adenomatoid hyperplasia of the duodenum with malignant changes accompanying intermediated-differentiated adenocarcinoma of upper and middle intrahepatic biliary duct .

病理类型：十二指肠乳头高分化腺癌3例，胰头内分泌小细胞癌1例，十二指肠乳头腺瘤样增生恶变，肝胆管中上段中分化腺癌1例。